Related Experiment Video
Updated: May 4, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
A case of hypomania during nicotine cessation treatment with bupropion
Karine Giasson-Gariépy, Didier Jutras-Aswad1
1Research Center, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada. didier.jutras-aswad@umontreal.ca.
Abstract:
Antidepressants can increase the spontaneous risk of hypomania or mania when used for treatment in affective disorders. When prescribed as an antidepressant, bupropion is generally considered to have a lower relative risk of inducing mood shifts. We describe the case of a 67-year-old man known for dysthymic disorder in remission on quetiapine and venlafaxine who experienced a first lifetime episode of hypomania with the introduction of bupropion SR for smoking cessation. To the best of our knowledge, this is the first case report of bupropion-induced mood shift when used specifically for nicotine cessation in a nonbipolar patient. This case highlights the need for clinicians who prescribe bupropion for smoking cessation to perform regular and systematic mood follow-ups during treatment. These follow-ups could even be more important when bupropion is selected to quit smoking in a patient already taking an antidepressant.
More Related Videos
Related Concept Videos
Bipolar Disorder
Mania and Antimanic Drugs: Overview
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Antidepressant Drugs: MAOIs and Other Agents
Drug Dependence
CNS Depressants: Alcohol and Nicotine

